FDA Green Lights Potential Coronavirus Recovery Drug

Gilead Sciences' drug Remdesivir has shown promise in treating COVID-19, leading to FDA emergency use approval for severe cases. President Trump endorsed the drug, highlighting its potential. Studies indicate it reduces recovery times by 31% and shortens hospital stays by four days. Over half of the test subjects showed improvement. While the FDA allows its experimental use, Remdesivir must undergo further testing before formal approval as a coronavirus treatment.

What was the average reduction in hospitalization time for patients in the previous study?

What must happen before Remdesivir can receive formal approval as a coronavirus treatment?